BioCentury | Sep 30, 2013
Finance

Broader minded in Canada

...Inc. (NASDAQ:VRTX) bought in 2009 for $413.1 million in cash and stock; and cancer company Gemin X Pharmaceuticals Inc....
BioCentury | Sep 23, 2013
Finance

Quebec engine

...million. Therillia will be run by the management team of Sanderling's former Canadian portfolio company Gemin X Pharmaceuticals Inc....
...lower in Canada than the U.S.," noted Therillia CEO Michael Dixon, who was CFO at Gemin X...
BioCentury | Jun 25, 2012
Company News

Flexion Therapeutics management update

...Mass. Business: Musculoskeletal Hired: Arthur Fratamico as CBO, a newly created position, formerly CBO of Gemin X Pharmaceuticals Inc....
BioCentury | Apr 16, 2012
Finance

Heeding health economics

...company sales to Cephalon Inc. (now part of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA). Cephalon bought Gemin X Pharmaceuticals Inc....
BioCentury | Feb 27, 2012
Finance

Caxton team to Valence

...had several exits over the last six years, including last year's sale of cancer company Gemin X Pharmaceuticals Inc....
BioCentury | Aug 15, 2011
Product Development

Powering down cancer

...APO866 , which is in Phase II testing to treat cutaneous T cell lymphoma (CTCL). Gemin X Pharmaceuticals Inc....
BioCentury | Jun 13, 2011
Clinical News

Obatoclax: Phase II data

...performance status of 0 or 1 in 1Q12. Cephalon gained obatoclax through its acquisition of Gemin X Pharmaceuticals Inc....
BioCentury | Jun 8, 2011
Clinical News

Obatoclax to enter Phase III despite Phase II miss

...antagonist of B cell lymphoma 2 ( BCL-2 ; BCL2 ) through its acquisition of Gemin X Pharmaceuticals Inc....
BioCentury | Apr 18, 2011
Company News

Trevena management update

...of Prussia, Pa. Business: Cardiovascular, Neurology, Autoimmune Hired: Arthur Fratamico as CBO, formerly CBO of Gemin X Pharmaceuticals Inc....
BioCentury | Apr 4, 2011
Strategy

Half-A-Loaf Dilemma

...has announced six acquisitions since the beginning of 2009, including proposals to buy cancer plays Gemin X Pharmaceuticals Inc....
...in the B cell lymphoma 2 ( BCL2 ) family. The company proposed to acquire Gemin X...
...inhibitor from ChemGenex; and teglarinad, a prodrug of a nicotinamide phosphoribosyl transferase (NamPRT) inhibitor from Gemin X...
Items per page:
1 - 10 of 76
BioCentury | Sep 30, 2013
Finance

Broader minded in Canada

...Inc. (NASDAQ:VRTX) bought in 2009 for $413.1 million in cash and stock; and cancer company Gemin X Pharmaceuticals Inc....
BioCentury | Sep 23, 2013
Finance

Quebec engine

...million. Therillia will be run by the management team of Sanderling's former Canadian portfolio company Gemin X Pharmaceuticals Inc....
...lower in Canada than the U.S.," noted Therillia CEO Michael Dixon, who was CFO at Gemin X...
BioCentury | Jun 25, 2012
Company News

Flexion Therapeutics management update

...Mass. Business: Musculoskeletal Hired: Arthur Fratamico as CBO, a newly created position, formerly CBO of Gemin X Pharmaceuticals Inc....
BioCentury | Apr 16, 2012
Finance

Heeding health economics

...company sales to Cephalon Inc. (now part of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA). Cephalon bought Gemin X Pharmaceuticals Inc....
BioCentury | Feb 27, 2012
Finance

Caxton team to Valence

...had several exits over the last six years, including last year's sale of cancer company Gemin X Pharmaceuticals Inc....
BioCentury | Aug 15, 2011
Product Development

Powering down cancer

...APO866 , which is in Phase II testing to treat cutaneous T cell lymphoma (CTCL). Gemin X Pharmaceuticals Inc....
BioCentury | Jun 13, 2011
Clinical News

Obatoclax: Phase II data

...performance status of 0 or 1 in 1Q12. Cephalon gained obatoclax through its acquisition of Gemin X Pharmaceuticals Inc....
BioCentury | Jun 8, 2011
Clinical News

Obatoclax to enter Phase III despite Phase II miss

...antagonist of B cell lymphoma 2 ( BCL-2 ; BCL2 ) through its acquisition of Gemin X Pharmaceuticals Inc....
BioCentury | Apr 18, 2011
Company News

Trevena management update

...of Prussia, Pa. Business: Cardiovascular, Neurology, Autoimmune Hired: Arthur Fratamico as CBO, formerly CBO of Gemin X Pharmaceuticals Inc....
BioCentury | Apr 4, 2011
Strategy

Half-A-Loaf Dilemma

...has announced six acquisitions since the beginning of 2009, including proposals to buy cancer plays Gemin X Pharmaceuticals Inc....
...in the B cell lymphoma 2 ( BCL2 ) family. The company proposed to acquire Gemin X...
...inhibitor from ChemGenex; and teglarinad, a prodrug of a nicotinamide phosphoribosyl transferase (NamPRT) inhibitor from Gemin X...
Items per page:
1 - 10 of 76